Moderna (MRNA) Stock Slips After BofA Questions Its Valuation

The MRNA stock price fluctuated between $372 and $453.73 throughout the trading session with the volume trading being 53M shares, which represented a positive variation when compared to the three months average volume of 14M shares.

The share price of Moderna, Inc. (NasdaqGS:MRNA) dipped -15.64% to close Wednesday’s market session at $385.33, lower as compared to yesterday’s close which brings the market valuation of the company to $154.72B.

The 52-week high for the Moderna, Inc.’s shares is $497.49. That puts it -22.55% from that peak but still a massive gain since the share price dropped to a 52-week low of $54.21, while the S&P 500’s share price change was of 33%.

The company currently has a 258.26 P/E ratio and a price target of $184.92.

What does the trading volume tell us about the MRNA stock?

During the last trading session, Moderna, Inc. (NasdaqGS:MRNA) has seen growth in its daily volume. The daily volume was of 14M, while in the last 10 days the average was 27.04M and last three months – 14.11M.


Shrinking short interest

The Moderna, Inc.’s shares are seeing a decreasing short interest compared to the previous month. As of today, there are 11.83M shares being shorted which translates into 1.27 of a short ratio for MRNA, while in the previous month the shorted shares were 12.94M.

Moderna, Inc.’s (NasdaqGS:MRNA) financials

With a market cap of 154.72B, Moderna, Inc. holds a total cash of $7.74B that translates into $19.26 per share, while the total debt is of $279M.

The company has seen a decrease in the revenue with a year-over-year quarterly revenue growth percentage of 24,112.50%. The current revenue is of $2.73B that is $6.95 per share.

This is a not so fantastic sign for the future.